Based in Canada, MTI is a materials and photonics company that designs and develops optical filters and metamaterial-based systems, while Mediwise is a UK-based developer of wireless devices for medical diagnostics and monitoring purposes.
The transaction will strengthen the acquirer company’s position in the advanced materials market.
The acquisition will add TVA’s endovascular everlinQ system to BD’s product portfolio, which will be a complementary addition to its peripheral intervention offerings.
Based in the US, BD is a medical devices manufacturer and distributor, while TVA, also based in the US, is a developer of minimally invasive therapies for end-stage renal disease and peripheral vascular disease.
The transaction will enable BD to provide an innovative device to physicians treating patients suffering from chronic kidney disease (CKD) and requiring haemodialysis.
Based in the US, Boston Scientific is a developer of medical devices, while Cryterion Medical, also based in the US, is a developer of single-shot cryoablation platform for the treatment of atrial fibrillation (AF).
The acquisition will add Cryterion’s cryoballoon platform to Boston’s electrophysiology products portfolio and expand its atrial fibrillation therapy offerings.
Jiangsu Nanfang Medical Co plans to purchase a 70% interest in Jinagsu Vanguard Pharmaceutical Co for CNY1.0bn ($158.16m) through the issuance of shares.
Jiangsu Nanfang is engaged in the manufacturing and distribution of medical adhesive tapes and wound dressings, while Jinagsu Vanguard is a manufacturer of pharmaceutical products.
Both the companies involved in the transaction are based in China.
Based in Switzerland, JF Investments is a fund management company, while GenePlanet is a Slovenia-based company engaged in preventive genetic testing.
The transaction enables GenePlanet to expand its business in Asia and develop its health intelligence platform.